Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 13/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 13/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4394968 | 0.83 | ALDH1A1 (0.46) | ALDH1A1HDAC1HDAC6MEN1KMT2A | |
| SCHEMBL3837475 | 0.82 | HDAC1 (0.47) | LPAR1LPAR5ALDH1A1ALDH2HDAC1 | |
| SCHEMBL4391449 | 0.75 | MEP1B (0.40) | LPAR1LPAR5ALDH1A1ALDH2HDAC1 | |
| SCHEMBL21456600 | 0.73 | HDAC1 (0.41) | ALDH1A1HDAC1HDAC6SMN1; SMN2 | |
| SCHEMBL11120189 | 0.71 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| Hydrochloric Acid SCHEMBL5830761 | 0.70 | RARB (0.54) | ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11189806 | 0.70 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL7564084 | 0.67 | SLC6A2 (0.57) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL31040424 | 0.66 | GRM4 (0.38) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1566408 | 0.64 | ALDH1A1 (0.57) | LPAR1LPAR5ALDH1A1ALDH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | LPAR1 2294/4885LPAR5 3642/4885ALDH1A1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.